Since the aromatase inhibitor letrozole has already been shown to be an effective therapeutic drug for PCOS [46, 47], GPR1 may be useful as an alternative or adjunct target for PCOS therapy. The gene discussed is CYP19A1; the disease is polycystic ovary syndrome.